January 23, 2017 | Two biomed companies, Pluristem Therapeutics Ltd. and Can-Fite BioPharma Ltd., announced financing rounds at the end of last week. Pluristem raised $15 million, after enlarging its planned offering, while Can-Fite raised $5 million. In May, Pluristem, an Israeli company developing placenta-based therapy products, announced that it was awarded a NIS 12.7 million (approx. $3.3 million) grant from the Israel Innovation Authority (previously the Office of the Chief Scientist ‘OCS’) of the Israeli Ministry of Economy & Industry. The grant will support Clinical trials and R&D activities for calendar year 2016. Pluristem was founded in 2001 by Shai Meretzki. Can-Fite is an Israeli biopharmaceutical company founded in 1994 with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.